Effects of Presenilin 2 mutations associated with Familial Alzheimer's Disease on mitochondrial bioenergetics
Year: 2018
Type: article
Abstract: Alzheimer’s Disease (AD) is a neurodegenerative disorder of the central nervous system. It is mainly sporadic, however, a little percentage of cases is inherited (Familial AD, FAD) and due to autosomal dominant mutations on three different genes, coding for Amyloid Precursor Protein (APP), Presenilin 1 (PS1) and Presenilin 2 (PS2). Presenilins, mainly localized at Endoplasmic Reticulum (ER) membranes, are the catalytic core of the ɣ-secretase complex, although several ɣ-secretase-independent activities of PSs, such as modulation of neurites outgrowth, apoptosis, autophagy, synaptic functions and regulation of Ca2+ homeostasis, have been described. Ca2+, a key intracellular second messenger, is involved in multiple cellular functionalities. Interestingly, alterations in Ca2+ homeostasis have been proposed as an early event in different neurodegenerative diseases, including AD. Notably, FAD-PS mutants have been reported to be directly involved in these dysregulations. In our lab, it has been previously showed that PS2 expression, both WT and, more potently, FAD mutants (such as PS2-T122R), but not PS1, decreases the ER Ca2+ content, mainly by inhibiting SERCA pump activity. Moreover, PS2 increases ER-mitochondria physical and functional coupling, favouring the process of ER to mitochondria Ca2+ transfer. However, due to its effect on ER [Ca2+], which results in a lower amount of available Ca2+ within the ER, its expression dampens mitochondrial Ca2+ rises upon cell stimulation. Based on the well-established role of Ca2+ on mitochondrial metabolism, here we investigate the possible effects on mitochondrial functionalities of the complex balance between alterations in ER Ca2+ content and increased ER-mitochondria coupling, induced by FAD-PS2 mutants expression. A neuroblastoma cell line (SH-SY5Y) grown in a medium containing galactose, as a substitute of glucose, has been used. This growth condition enhances mitochondrial metabolism and results in an excellent experimental protocol to visualize possible mitochondrial defects. Lower total cellular ATP levels were measured in FAD-PS2-T122R expressing cells, grown either in glucose- or galactose-containing medium, with the reduction more evident in the latter condition, thus suggesting possible mitochondrial defects induced by PS2 expression. In order to investigate how Ca2+ dysregulation induced by PS2 could influence mitochondrial metabolism, we stimulated mitochondrial ATP production inducing ER Ca2+ release, followed by mitochondria Ca2+ uptake, using both bradykinin, as a maximal IP3R stimulation, and Fetal Calf Serum (FCS), as a more physiological stimulus. In both conditions, a reduction in mitochondrial ATP production, measured by a mitochondrial luciferase-based ATP probe, has been observed in cells expressing FAD-PS2, but not PS1. The defects in ATP synthesis were observed in SH-SY5Y, MEF, HT22 cells and in cortical neurons from PS2-N141I transgenic (Tg) mice (PS2.30H), by employing FRET-based ATP probes (ATeam 1.03) specifically targeted to the mitochondrial matrix or the nucleus. We also evaluated the glycolytic flux in these cells, by both employing a cytosolic luciferase-based ATP probe and measuring the extracellular medium acidification, but we did not observed any difference in these two parameters in FAD-PS2 expressing cells, compared to controls. In order to understand the mechanism through which PS2 causes the observed mitochondrial dysfunction, we firstly considered the marked Ca2+ dysregulation induced by PS2 expression. We thus decided to modulate Ca 2+ handling in control cells, to mimic the ER Ca2+ depletion caused by PS2 expression. We used two different approaches: i) treating control cells with a SERCA pump inhibitor (Cyclopiazonic acid, CPA), to partially reduce the ER Ca2+ content, or ii) overexpressing a mutated-MICU1 (MICU1mut), a component of the mitochondrial Ca2+ uniporter complex. Although both approaches were able to reduce the capacity of control cells to produce ATP, for similar mitochondrial Ca2+ uptake in control and PS2-expressing cells, a lower mitochondrial ATP production in FAD-PS2 expressing-cells compared to CPA-treated or MICU1mut expressing controls was still observed. Taken together, these results suggest that part of the FAD-PS2-induced defects in mitochondrial metabolism is due to a reduced ER Ca2+ content and, consequently, mitochondrial Ca2+ uptake, negatively regulating the Ca2+-dependent mitochondrial metabolism. However, additional mechanisms, induced by FAD-PS2, are likely involved in mitochondrial dysfunctions. We thus evaluated the respiratory chain activity measuring the oxygen consumption rate (OCR): both basal and maximal OCR were reduced in FAD-PS2, but not in FAD-PS1, expressing cells. Moreover, a reduced mitochondrial ATP-linked respiration was measured in PS2-T122R expressing cells, while no difference was found in the proton leak. Since the expression levels of the ATP synthase and the respiratory chain complexes were not affected by FAD-PS2 expression, and isolated mitochondria from WT and PS2-N141I Tg mice did not reveal substantial differences in mitochondrial respiratory activity, we reasoned that the impairment in ATP production observed in intact cells is not due to defective mitochondria per se, but likely depends on the cellular environment. Importantly, for a proper mitochondrial metabolism, the right amount of substrates produced through glycolysis in the cytosol has to reach the mitochondrial matrix to support the TCA cycle and the respiratory chain activity. Hexokinase1 (HK1), the enzyme that catalyses the first step of glycolysis converting glucose to glucose 6-phosphate, seems to be involved in the modulation of the mitochondrial substrates import, since HK1 interaction/detachment with/from mitochondria can modulate mitochondrial substrates permeability. Firstly, we measured a reduced HK1-mitochondria co-localization in FAD-PS2 expressing SH-SY5Y cells, in FAD-PS2 patient-derived fibroblasts and in primary cortical neurons from FAD-PS2-N141I Tg mice, compared to controls. By mimicking the FAD-PS2 effect on HK1-mitochondria interaction treating control cells with Clotrimazole, a drug capable to detach HK1 from mitochondria, a reduced mitochondrial ATP production was measured; however, the impairment on ATP production induced by clotrimazole was less marked than that caused by FAD-PS2 expression. These results indicate that, although the detachment of HK1 from mitochondria plays a pivotal role in causing mitochondrial defects upon FAD-PS2 expression, the PS2-induced Ca2+ dysregulation, described above, may additionally contribute to the overall mitochondrial impairment. These results have been confirmed also by a genetic approach. We down-regulated the expression of endogenous HK1, by specific siRNAs, and we rescued HK1 protein level by over-expressing siRNA-resistant full-length- (FL-HK1) or truncated- (Tr-HK1) HK1. This latter protein lacks the mitochondrial binding domain, but still conserves the catalytic activity. We found that, upon endogenous HK1 silencing, mitochondrial ATP production is strongly reduced. Interestingly, while the re-expression of FL-HK1 was able to completely rescue the reduced ATP production, the Tr-HK1 was unable to do it, again confirming that the detachment of HK1 from mitochondria is involved in the mitochondrial impairment caused by FAD-PS2. Related to HK1 and its role in the regulation of mitochondrial substrates permeability, an increase in the cytosolic amount of pyruvate was measured in FAD-PS2 expressing cells, compared to controls, employing a cytosolic FRET-based pyruvate probe, Pyronic. Importantly, by pharmacologically blocking mitochondrial pyruvate carrier (MPC), the protein responsible for mitochondrial pyruvate uptake, with two different drugs, UK5099 and Pioglitazone, no differences were anymore detected between control and FAD-PS2 expressing cells, suggesting that FAD-PS2 is acting on this pathway. Overall, we have showed that FAD-PS2 mutants decrease cellular ATP levels, in particular mitochondrial ATP production, by two different mechanisms: 1) causing Ca2+ dysregulation, mainly decreasing the ER Ca2+ content, and thus the amount of Ca2+ available for mitochondrial Ca2+ uptake; 2) inducing the detachment of HK1 from mitochondria, likely affecting the availability of substrates (i.e., pyruvate) for mitochondria. Further experiments will be aimed at: i) evaluate the impact of the PS2-dependent strengthened ER-mitochondria coupling on the reported mitochondrial defects; ii) defining the molecular mechanism through which FAD- PS2 mutants affect HK1 intracellular distribution; iii) evaluate the impact of these alterations on the onset/progression of the AD phenotype.
Author: Alice Rossi
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Keywords: presenilin 2, familial Alzheimer's disease, mitochondrial bioenergetics, mitochondrial calcium, sarcoplasmic reticulum Ca2+-ATPase, endoplasmic reticulum calcium, galactose metabolism, ATP levels, mitochondrial respiration, mitochondrial membrane potential, mitochondrial fission, mitochondrial biogenesis, secretases
Open Access status: green
OpenAlex ID: W2921912673
